Transdermal estradiol/progestogen agent patch and its production
First Claim
1. A transdermal patch for the release through the skin of estradiol and norethisterone acetate (NETA), consisting of an outer backing layers a matrix and a protective release liner, wherein the backing layer is impermeable to the drugs and supports the matrix, the matrix being a crosslinked pressure-sensitive adhesive copolymer matrix in which the active ingredients are dissolved or dispersed and wherein the matrix is covered by the protective release liner impermeable to the drugs that must be removed immediately before the application of the patch onto the skin, wherein said crosslinked pressure sensitive adhesive copolymer matrix is obtained by radical copolymerization of between 50 to 85% 2-ethylhexyl acrylate, 3.5 to 6.5% hydroxyethyl acrylate, 16 to 35% vinylacetate and up to 0.3% glycidyl methacrylate and, optionally, in the presence of substances including a cross-linking agent and a crystallization preventative, suitable to improve the stability and/or performance of the patch, and wherein estradiol and NETA are present in a supersaturated solid solution.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention concerns a transdermal patch for the release through the skin of estradiol and a progestogen agent and a process for its production.
-
Citations
23 Claims
- 1. A transdermal patch for the release through the skin of estradiol and norethisterone acetate (NETA), consisting of an outer backing layers a matrix and a protective release liner, wherein the backing layer is impermeable to the drugs and supports the matrix, the matrix being a crosslinked pressure-sensitive adhesive copolymer matrix in which the active ingredients are dissolved or dispersed and wherein the matrix is covered by the protective release liner impermeable to the drugs that must be removed immediately before the application of the patch onto the skin, wherein said crosslinked pressure sensitive adhesive copolymer matrix is obtained by radical copolymerization of between 50 to 85% 2-ethylhexyl acrylate, 3.5 to 6.5% hydroxyethyl acrylate, 16 to 35% vinylacetate and up to 0.3% glycidyl methacrylate and, optionally, in the presence of substances including a cross-linking agent and a crystallization preventative, suitable to improve the stability and/or performance of the patch, and wherein estradiol and NETA are present in a supersaturated solid solution.
-
16. A process for the production of a transdermal patch characterized by the following measures:
-
a solution ofthe crosslinked pressure-sensitive copolymer matrix and of estradiol and norethisterone acetate (NETA) as active ingredients is spread onto a foil that shall become the release liner, and the solvents are evaporated, at a temperature of from 35 to 90°
C., at atmospheric pressure or under reduced pressure and then covered by a foil which shall become the backing layer;
orthe solution of the crosslinked pressure-sensitive copolymer matrix and of estradiol and the progestogen agent as active ingredients is spread on a silicone-coated intermediate liner made of paper or polyester, the solvents are evaporated, at a temperature of from 35 to 90°
C., at atmospheric pressure or under reduced pressure,a foil that shall become the protective release liner is stuck on the matrix supported by the intermediate liner, and the matrix is transferred from the intermediate liner to the release liner and a foil that shall become the backing layer is stuck on the matrix supported by the release liner;
orthe solution of the crosslinked pressure-sensitive copolymer matrix and of estradiol and the progestogen agent as active ingredients is spread onto a foil that shall become the backing layer, and the solvents are evaporated, at a temperature of from 35 to 90°
C., at atmospheric pressure or under reduced pressure and the release liner is stuck on the matrix supported by the backing layer. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23)
-
Specification